Achillion Pharmaceuticals Inc. (ACHN)’s Financial Results Comparing With ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) and ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) compete with each other in the Biotechnology sector. We will analyze and compare their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Achillion Pharmaceuticals Inc. N/A 0.00 70.27M -0.56 0.00
ZIOPHARM Oncology Inc. N/A 4649.11 137.25M -0.54 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 has Achillion Pharmaceuticals Inc. and ZIOPHARM Oncology Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Achillion Pharmaceuticals Inc. 0.00% -25.5% -24.7%
ZIOPHARM Oncology Inc. 0.00% 58.6% -89.9%

Volatility & Risk

Achillion Pharmaceuticals Inc. is 145.00% more volatile than S&P 500 because the company has a beta of 2.45. ZIOPHARM Oncology Inc. on the other hand, has 2.57 beta which makes it 157.00% more volatile compared to S&P 500.

Liquidity

The Current Ratio and Quick Ratio of Achillion Pharmaceuticals Inc. are 33.2 and 33.2 respectively. Its competitor ZIOPHARM Oncology Inc.’s Current Ratio is 0.8 and its Quick Ratio is 0.8. Achillion Pharmaceuticals Inc. can pay off short and long-term obligations better than ZIOPHARM Oncology Inc.

Analyst Ratings

The Ratings and Recommendations for Achillion Pharmaceuticals Inc. and ZIOPHARM Oncology Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Achillion Pharmaceuticals Inc. 0 0 1 3.00
ZIOPHARM Oncology Inc. 0 0 3 3.00

Achillion Pharmaceuticals Inc. has a 86.34% upside potential and an average price target of $6. ZIOPHARM Oncology Inc. on the other hand boasts of a $6 consensus price target and a 42.86% potential upside. Based on the analysts view we can conclude, Achillion Pharmaceuticals Inc. is looking more favorable than ZIOPHARM Oncology Inc.

Insider and Institutional Ownership

The shares of both Achillion Pharmaceuticals Inc. and ZIOPHARM Oncology Inc. are owned by institutional investors at 79.2% and 39.8% respectively. About 0.15% of Achillion Pharmaceuticals Inc.’s share are held by insiders. Comparatively, 1.7% are ZIOPHARM Oncology Inc.’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Achillion Pharmaceuticals Inc. 0.38% 20.09% -9.31% -17.03% -20.78% 65.41%
ZIOPHARM Oncology Inc. -12.58% 20.98% -25.14% -3.9% -25.14% 44.92%

For the past year Achillion Pharmaceuticals Inc. was more bullish than ZIOPHARM Oncology Inc.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. Its drug candidates for treating chronic hepatitis C virus (HCV) infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. The company is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, a drug candidate that is delivered topically or locally; and collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize antiviral drug candidates for treating HCV infection. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to IntrexonÂ’s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma (GBM). Its synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer. The company, under its license agreement with The University of Texas MD Anderson Cancer Center, along with Intrexon hold license to certain technologies relating to novel chimeric antigen receptor (CAR) T cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer cells, and T cell receptors. It also has a research and development agreement with the National Cancer Institute utilizing Sleeping Beauty System to generate T cells receptors for the treatment of solid tumors. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.